Fig. 2

a and b Overall Survival (OS) (Fig. 1a) and Event-free Survival (EFS) of 59 AML patients with extramedullary disease dichotomized to the LOX-high (n = 31) and LOX-low (n = 28) group. LOX-high patients are denoted in green, LOX-low patients are denoted in blue color. The logarithmic logLOX value = 2.0403 (109 ng/mL) was used to dichotomize all patients in both groups, respectively. For LOX-high patients 3-year OS was 13% (95% CI, 1–25%) and for LOX-low patients 43% (95% CI, 23–63%), p = .002. Three-year EFS for LOX-high patients was 6% (95% CI, 0–15%) and for LOX-low patients 36% (95% CI, 17–54%), p = 0.008